OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Sophia Frentzas, Anna Rachelle Mislang, Charlotte Lemech, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008037-e008037
Open Access | Times Cited: 14
Sophia Frentzas, Anna Rachelle Mislang, Charlotte Lemech, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008037-e008037
Open Access | Times Cited: 14
Showing 14 citing articles:
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches
Shabnam Eghbali, Thatcher Heumann
Cancers (2025) Vol. 17, Iss. 2, pp. 236-236
Open Access | Times Cited: 1
Shabnam Eghbali, Thatcher Heumann
Cancers (2025) Vol. 17, Iss. 2, pp. 236-236
Open Access | Times Cited: 1
Ivonescimab: First Approval
Sohita Dhillon
Drugs (2024) Vol. 84, Iss. 9, pp. 1135-1142
Closed Access | Times Cited: 7
Sohita Dhillon
Drugs (2024) Vol. 84, Iss. 9, pp. 1135-1142
Closed Access | Times Cited: 7
Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways
Songyu Shen, Yihan Hong, Jiajun Huang, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 16-28
Closed Access | Times Cited: 6
Songyu Shen, Yihan Hong, Jiajun Huang, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 16-28
Closed Access | Times Cited: 6
Advancements in a novel model of autophagy and immune network regulation in radioresistance of cancer stem cells
Leyao Li, Xin Wang, Mei Jiang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117420-117420
Open Access | Times Cited: 4
Leyao Li, Xin Wang, Mei Jiang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117420-117420
Open Access | Times Cited: 4
Advances in targeting tumor microenvironment for immunotherapy
Lugang Wang, Liubo Zhang, Zhen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Lugang Wang, Liubo Zhang, Zhen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
An updated review on immune checkpoint inhibitor-induced colitis: epidemiology, pathogenesis, treatment strategies, and the role of traditional Chinese medicine
Huijing Dong, Yanmei Peng, Xinmeng Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Huijing Dong, Yanmei Peng, Xinmeng Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors
Feng‐Hua Wang, Xiaoli Wei, Yulong Zheng, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Feng‐Hua Wang, Xiaoli Wei, Yulong Zheng, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma
Siyu Xia, Lihua Chen, Yu Min, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e010069-e010069
Open Access | Times Cited: 1
Siyu Xia, Lihua Chen, Yu Min, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e010069-e010069
Open Access | Times Cited: 1
Emerging strategies to overcome ovarian cancer: advances in immunotherapy
Tatiana Massariol Pimenta, Josiany Carlos de Souza, Bárbara da Silva Martins, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Tatiana Massariol Pimenta, Josiany Carlos de Souza, Bárbara da Silva Martins, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Machine learning identifies immune-based biomarkers that predict efficacy of anti-angiogenesis-based therapies in advanced lung cancer
Peixin Chen, Lei Cheng, Chao Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113588-113588
Closed Access
Peixin Chen, Lei Cheng, Chao Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113588-113588
Closed Access
